Depemokimab Trial for COPD
Phase 3
960
about 4.2 years
40–80
54 sites in AL, CO, FL +16
What this study is about
This trial is testing depemokimab, a new medication, as an add-on treatment for adults with moderate to severe COPD and type 2 inflammation. The goal is to see if depemokimab helps improve symptoms in people who don't respond well to standard treatments.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Depemokimab
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
monoclonal antibody
Secondary: Annualized Rate of Exacerbations Requiring Emergency Department (ED) Visit or Hospitalization, Change from Baseline in Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS: COPD) Total Score at Week 52, Change from Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 52
Respiratory